TANDEARIL Drug Patent Profile
✉ Email this page to a colleague
When do Tandearil patents expire, and what generic alternatives are available?
Tandearil is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in TANDEARIL is oxyphenbutazone. There is one drug master file entry for this compound. Additional details are available on the oxyphenbutazone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TANDEARIL?
- What are the global sales for TANDEARIL?
- What is Average Wholesale Price for TANDEARIL?
Summary for TANDEARIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 58 |
| Patent Applications: | 6,437 |
| DailyMed Link: | TANDEARIL at DailyMed |
US Patents and Regulatory Information for TANDEARIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TANDEARIL | oxyphenbutazone | TABLET;ORAL | 012542-004 | Sep 3, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
